Novel Device used to Optimize Aerosol Drug Delivery for Pulmonary Hypertension Treatment

摘要 雾化吸入治疗是呼吸治疗的基石之一。空中的大小 颗粒决定了它们在肺内的沉积模式， 吸入疗法在该SBIR项目的第1阶段，BridgeSource Medical（BSM）建议： 开发具有可变气溶胶液滴尺寸和致动时间的呼吸适应性雾化器。 这可以用于向全身性患者施用精确剂量的药物。 循环的效率比目前可用的气溶胶输送装置， 需要严格的患者呼吸定时的小容量自适应气雾剂递送（AAD）雾化器， 但不改变液滴尺寸。雾化器将特别有益于给药 治疗患有呼吸系统疾病的老年患者的药物， 高血压，治疗时间长，对患者呼吸要求严格， 遵守不佳。最终目标是开发一种临床工具， 美国食品和药物管理局（FDA）作为一个有效系统， 针对不能容易地遵守严格呼吸操作的患者的制剂， 比如那些晚期肺病患者。

Abstract Aerosol inhalation therapy is one of the cornerstones of respiratory therapy. The size of airborne particles determines their deposition pattern within the lungs and therefore, the efficacy of inhalation therapy. In this Phase 1 SBIR project, BridgeSource Medical (BSM) proposes to develop a breath-adaptive nebulizer with variable aerosol droplet sizes and actuation times. This can be used to administer precise doses of pharmaceutical drugs to the systemic circulation with much greater efficiency than currently available aerosol delivery devices like small-volume adaptive aerosol delivery (AAD) nebulizers that require strict patient breath timing, but do not vary droplet size. The nebulizer would be particularly beneficial in the administration of medications to treat elderly patients with respiratory conditions such as pulmonary hypertension, where long treatment times and strict requirements on patient breathing lead to poor compliance. The ultimate goal will be to develop a clinical tool that would be approved by the Food and Drug Administration (FDA) as an effective system to nebulize several drug formulations targeted for patients who cannot easily comply with strict breathing maneuvers, such as the those with advanced lung disease.